Current Report Filing (8-k)
April 29 2019 - 04:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
CURRENT
REPORT
PURSUANT TO
SECTION 13 OR 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of Earliest Event Reported): April 26,
2019
Cleveland
BioLabs, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
|
|
|
DELAWARE
|
001-32954
|
20-0077155
|
(State or
Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification Number)
|
|
73 High
Street
Buffalo, NY
14203
|
|
(Address of
Principal Executive Offices and zip code)
|
|
|
|
|
(716)
849-6810
|
|
(Registrant's
Telephone Number, Including Area Code)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company o
If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. o
Item 5.07
Submission of Matters to a Vote of Security Holders.
Cleveland BioLabs, Inc. (the
" Company
") held its Annual
Meeting of Stockholders on April 26, 2019 (the "
2019
Annual Meeting ") in Buffalo, New York. The
results of matters submitted to a stockholder vote at the 2019
Annual Meeting are as follows:
Proposal
1: Election of Directors . Seven nominees were elected to
serve on the Company's board of directors until the next annual
meeting of stockholders and until their successors are elected and
qualified with the votes set forth below:
|
|
|
|
|
Nominee
|
For
|
Withheld
|
Broker Non-Votes
|
Alexander
Andryushechkin
|
7,201,130
|
52,955
|
3,389,788
|
Anna Evdokimova
|
7,201,384
|
52,701
|
3,389,788
|
Ivan Fedyunin
|
7,202,060
|
52,025
|
3,389,788
|
Ivan Persiyanov
|
7,201,603
|
52,482
|
3,389,788
|
Randy S. Saluck
|
7,211,425
|
42,660
|
3,389,788
|
Daniil Talyanskiy
|
7,201,168
|
52,917
|
3,389,788
|
Lea Verny
|
7,204,446
|
49,639
|
3,389,788
|
Proposal
2: Ratification of Meaden & Moore, Ltd. as the independent
registered public accounting firm for fiscal year ending December
31, 2019 .
The selection of Meaden & Moore, Ltd. as the Company's
independent registered public accounting firm for the fiscal year
ending December 31, 2019 was ratified with the votes set forth
below:
|
|
|
|
For
|
Against
|
Abstain
|
10,403,842
|
98,432
|
141,599
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cleveland
BioLabs, Inc.
|
|
Date: April 29,
2019
|
By:
/s/ YAKOV KOGAN
|
Name: Yakov
Kogan
Title: Chief
Executive Officer
Cleveland BioLabs (NASDAQ:CBLI)
Historical Stock Chart
From Dec 2020 to Jan 2021
Cleveland BioLabs (NASDAQ:CBLI)
Historical Stock Chart
From Jan 2020 to Jan 2021